A growing oncology pipeline and antibody platform provide multiple potential growth drivers. 🟢 $PCVX — BUY / SPECULATIVE — Vaccine-development upside is substantial, but clinical-stage risk remains high. 🟢 $ILMN — BUY — Genomics demand and improving execution could support a longer-term sequencing recovery. 🟢 $TWST — BUY / SPECULATIVE — Synthetic DNA demand gives Twist exposure to biotech research and next-generation medicine. 🟡 $TXG — HOLD — Single-cell analysis remains strategically important, but I'd want stronger fundamental confirmation before chasing the breakout. 🟡 $GRAL — HOLD / SPECULATIVE — Galleri offers enormous cancer-screening potential, but reimbursement, adoption and clinical validation remain important risks. 🟢 $GH — BUY / SPECULATIVE — Liquid-biopsy adoption provides a compelling precision-oncology growth opportunity. 🟡 $CRL — HOLD — A life-science recovery can help, but CRO demand is less compelling than the strongest genomics stories. 🟢 $HNGE — BUY — Digital musculoskeletal healthcare combines technology with a large addressable healthcare market. REFINERS — THE ENERGY TRADE KEEPS DELIVERING 🟢 $VLO — BUY — Tight global refining capacity and strong product margins remain favorable for efficient refiners. 🟢 $MPC — BUY — Scale, refining strength and shareholder returns make Marathon one of the higher-quality refinery plays. 🟢 $PBF — BUY / HIGH RISK — Strong refining margins create substantial earnings leverage, but the stock is considerably more cyclical. 🟡 $CVI — HOLD — Refining conditions are favorable, but company-specific execution and volatility warrant more caution. Refining has been a powerful 2026 trade: as of Oct. 2, $PBF, $MPC and $VLO were up roughly 203%, 163% and 153% YTD, respectively. 🇧🇷 BRAZIL — GLOBAL MONEY IS COMING BACK 🟢 $PBR / $PBR.